Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status approved; investigational
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 0781-9253; 14096-121; 81955-0012; 16729-306; 55150-393; 63323-771; 68001-527; 69097-368; 69097-805; 71288-153; 72485-201; 65129-1222; 68554-0104; 72606-558; 53183-4011; 43598-678; 59572-102; 51916-350; 83137-0006; 16714-927; 43817-906; 59572-730; 68001-504; 71288-115; 63660-0010; 0781-3253; 42385-312; 66529-0013; 54893-0029; 82920-015; 68001-313; 42385-719; 43598-305; 16714-578; 51991-797; 64679-096; 70121-1237; 63592-1800; 0143-9606; 43598-143; 43598-465; 59572-740
UNII M801H13NRU
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal infarct24.01.11.004; 20.01.07.0080.000168%Not Available
Renal tubular acidosis20.05.03.003; 14.01.01.0050.000112%Not Available
Respiratory disorder22.02.07.0020.001791%Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.003134%
Retinal detachment12.01.04.004; 06.09.03.0030.000112%
Retinal vein occlusion24.01.07.006; 06.10.01.0100.000112%Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinorrhoea22.12.03.021--
Rhonchi22.12.01.013--Not Available
Road traffic accident12.01.08.006--Not Available
Sarcoma16.33.01.002; 15.09.03.0020.000112%Not Available
Second primary malignancy16.16.01.0140.000280%
Seizure17.12.03.001--
Sepsis11.01.11.003--
Septic shock24.06.02.011; 11.01.11.004--Not Available
Shock24.06.02.0020.000783%Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.0070.000728%Not Available
Skin exfoliation23.03.07.0030.000638%Not Available
Skin irritation23.03.04.0090.000302%Not Available
Skin lesion23.03.03.0100.000694%Not Available
Skin necrosis23.03.03.0110.000280%Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000616%Not Available
Spleen disorder01.09.02.0030.000112%Not Available
Splenic infarction24.04.08.024; 01.09.02.0040.000336%Not Available
Splenomegaly01.09.02.0010.000616%Not Available
Squamous cell carcinoma16.16.01.0020.000168%Not Available
Stomatitis07.05.06.005--
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.000560%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene